RxDoctor Payments DataLook up a doctor →

Amir Kaki, MD

Interventional Cardiology · Detroit, MINPI 1831154798

Payments from drug & device makers

$2,268,549in general payments, 2019–2025

Across 2,516 payments — averaging $901.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$851K
  • Medtronic$296K
  • Cathworks, Inc.$263K
  • Inari Medical, Inc.$135K
  • Abbott$104K
  • Saranas, Inc.$86K
  • plus $533K from 54 others
$1,361in research payments, 2019–2025

Across 14 payments — averaging $97.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$1K
  • ZOLL Circulation Inc$220

What the payments were for

  • Consulting fees$503,80728%
  • Speaking & faculty fees$1,010,37057%
  • Grants$1,6060%
  • Travel & lodging$162,6979%
  • Food & beverage$81,2425%
  • Education$4570%
  • Other$17,7921%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abiomed560$851,245
Medtronic(2 entities)128$295,718
Cathworks, Inc.94$263,104
Inari Medical, Inc.114$134,871
Abbott163$103,817
Saranas, Inc.54$85,845
Shockwave Medical, Inc49$85,616
Cardiovascular Systems Inc.101$82,916
Amgen103$82,330
Merck86$71,949
AstraZeneca79$33,519
M.a. Med Alliance S.A.2$23,895
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)61$22,865
Angiodynamics, Inc.5$17,827
Recor Medical Inc35$16,761
Novartis87$11,932
Venclose Inc.11$10,592
Terumo Medical Corporation24$9,804
E.r. Squibb & Sons, L.L.C.69$9,031
Pfizer59$7,809
Penumbra, Inc.13$6,850
Chiesi USA, Inc.15$5,845
Stryker3$4,793
Boston Scientific66$4,677
Siemens Medical Solutions USA, Inc.6$4,251
Philips North America LLC8$3,842
Edwards Lifesciences15$1,716
Intuitive Surgical1$1,200
GSK70$1,173
Livanova USA, Inc.4$1,033
Ablative Solutions, Inc.11$1,010
Cagent Vascular Inc26$1,005
Johnson & Johnson68$860
Kestra Medical Technology Services, Inc.23$802
Lilly USA, LLC30$720
Cardinal Health 200 LLC44$713
Impulse Dynamics (USA) Inc.22$640
Boehringer Ingelheim20$485
Tactile Systems Technology Inc24$467
Novo Nordisk25$452
Asahi Intecc USA, Inc.3$342
Bard Peripheral Vascular, Inc.11$277
Teleflex LLC4$259
ZOLL Circulation Inc5$249
Astellas Pharma US Inc3$212
Vasorum USA Inc.1$200
Cvrx, Inc.5$189
Bayer8$174
Actelion Pharmaceuticals US, Inc.5$171
Bridgebio Pharma, Inc.10$169
Cardiva Medical, Inc.6$162
Getinge USA Sales, LLC7$158
Arrow International, Inc.1$153
Imperative Care, Inc3$145
Opsens Inc.2$144
Preventice Services, LLC10$132
Avinger Inc.1$130
Lexicon Pharmaceuticals, Inc.6$125
Inspire Medical Systems, Inc.1$124
Baxter Healthcare2$104

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,268,549 in reported general payments places this provider in the 95th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$616,240
Medicare patients
595
Services billed
7,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban306$261,401
EntrestoSacubitril/Valsartan240$228,132
MounjaroTirzepatide150$152,801
BrilintaTicagrelor165$96,769
OzempicSemaglutide69$84,564
XareltoRivaroxaban89$76,284
FarxigaDapagliflozin Propanediol87$76,039
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$47,469
Repatha SureclickEvolocumab66$46,829
JardianceEmpagliflozin43$39,826
TrulicityDulaglutide15$24,760
VerquvoVericiguat23$24,090
Famotidine44$5,219
Ranolazine ErRanolazine97$3,877
ClopidogrelClopidogrel Bisulfate331$3,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$7,809$261,401306 claims
NovartisEntresto$11,932$228,132240 claims
Lilly USA, LLCMounjaro, Trulicity$720$177,561165 claims
AstraZenecaBrilinta, Farxiga$33,519$172,808252 claims
Novo NordiskOzempic$452$84,56469 claims
Johnson & JohnsonXarelto$860$76,28489 claims
GSKTrelegy Ellipta$1,173$47,46973 claims
Boehringer IngelheimJardiance$485$39,82643 claims
MerckVerquvo$71,949$24,09023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →